Prognosis biomarkers in MOGAD: What can we learn from observational studies?

Area of Science:

• Neuroimmunology
• Demyelinating Diseases of the Central Nervous System

Background:

• Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a distinct inflammatory demyelinating disorder of the CNS.
• MOGAD pathologically differs from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).
• Observational studies suggest MOGAD is often monophasic with no clear progression, emphasizing early intervention.

Purpose of the Study:

• To identify hallmarks for relapse risk and long-term prognosis in MOGAD.
• To explore optimal management strategies for MOGAD attacks.
• To define treatment windows for modifying potential relapsing disease courses.

Main Methods:

• Review of observational studies on MOGAD.
• Analysis of clinical, biological, and imaging biomarkers.
• Evaluation of treatment outcomes and disease course.

Main Results:

• MOGAD is characterized by inflammatory demyelination, differing from MS and NMOSD.
• Early and aggressive anti-inflammatory treatment during attacks is associated with better recovery.
• Key biomarkers for relapse risk and prognosis are under investigation.

Conclusions:

• MOGAD requires distinct management approaches compared to MS and NMOSD.
• Timely and potent anti-inflammatory therapies are essential for MOGAD patients.
• Further research is needed to optimize treatment and predict long-term outcomes in MOGAD.